- Investing Ideas
- Danish Pharmaceuticals & Biotech Potentially Undervalued Companies
Danish Pharmaceuticals & Biotech Potentially Undervalued Companies
Results
6
Companies with a Value score of at least 3, ordered by Value score
6 companies
Bavarian Nordic
Market Cap: DKK 14.4b
Develops, manufactures, and supplies life-saving vaccines.
BAVA
DKK 189.00
7D
6.7%
1Y
-20.2%
H. Lundbeck
Market Cap: DKK 42.1b
Engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.
HLUN B
DKK 43.90
7D
5.8%
1Y
13.7%
Novo Nordisk
Market Cap: DKK 1.3t
Engages in the research and development, manufacture, and distribution of pharmaceutical products.
NOVO B
DKK 296.35
7D
-3.5%
1Y
-14.9%
H. Lundbeck
Market Cap: DKK 42.1b
Engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.
HLUN A
DKK 36.85
7D
3.9%
1Y
13.2%
Gubra
Market Cap: DKK 6.2b
A disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally.
GUBRA
DKK 380.80
7D
0.7%
1Y
7.3%
Strategic Partners
Market Cap: DKK 29.0m
Does not have significant operations.
STRAP
DKK 695.00
7D
-6.7%
1Y
-30.8%